Compare Merck & Co., Inc. (MRK) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs United Microelectronics Corp — how do they compare? Merck & Co., Inc. trades at $133.58 (market cap $321.77B), while United Microelectronics Corp trades at $19.49 (market cap $47.81B). The key difference: Merck & Co., Inc. is far larger — about 6.7× United Microelectronics Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | UMC | |
|---|---|---|
Market Cap | $321.77B | $47.81B |
Sector | Health | Technology |
52-Week High | $131.84 | $28.02 |
52-Week Low | $77.60 | $6.58 |
Enterprise Value | $368.53B | $44.93B |
Dividend Yield | 2.61% | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
UMC trades at $19.40, up 3.25% with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.54 EPS, and announced fab expansions in Singapore and Taiwan to meet AI demand. Revenue growth is projected to rise to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow turned positive in 2025 at $5.66 billion, supporting strategic investments.
Outlook is positive due to AI-driven demand and operational execution, but risks include competitive pressures and capital expenditure volatility. Analysts show mixed sentiment with 26.7% buy ratings, highlighting cautious optimism amid expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
